Administration of 98% ethanol destroys tissues by coagulative necrosis. In the rat bearing 1,2-dimethylhydrazine-induced colonic carcinoma which has spread to the liver, direct injection of 0.1-0.2 ml ethanol into each of the hepatic metastases at the time of total colectomy afforded a significant survival advantage relative to colectomy alone (20.1 + 0.2 vs 12.8 + 0.2 months of age, mean _+ SEM, n 20, p < 0.01 by the Mann-Whitney U test). A pilot study was, therefore, carried out (2 women and 4 men, age range 43 to 71 years mean 56) to examine the clinical significance of these observations in patients with multiple hepatic metastases from carcinoma of the sigmoid colon. The tumour was resected then all palpable hepatic secondaries were injected with 1-1.5 ml of 98% ethanol. Two weeks post-operatively and thereafter once every two months any hepatic lesions detected ultrasonically were similarly treated percutaneously. All the patients tolerated this treatment without any observed distress or adverse effects. Their mean survival measured from the time of tumour resection until death from any cause was 20 months (range 17 to 26 months). The survival gain afforded by chemonecrosis in addition to its simplicity and safety deserves further consideration to assess the exact role of this method in the treatment of liver metastases from colonic cancer.
INTRODUCTION
Carcinoma of the large bowel is the second leading cause of death from cancer in Western industrial countries. The most important prognostic factor for long-term survival of patients is the extent of tumour at the time of diagnosis. The high incidence and mortality rates of colonic cancer stress the need for improved therapeutic modalities that can combat this disease more effectively.
Liver metastases are present on initial diagnosis of large bowel cancer in 25 to 30% of patients1-3. Even after curative resection of the primary colorectal tumour between 40 and 60% of patients will develop recurrence and about 20 to 25% of them will have only liver metastases3'4. Once hepatic secondaries have developed, the prognosis is poor, with an expected median survival time of only a few months.
A review from the Mayo clinic showed that 20% of patients with solitary liver metastases from colorectal cancer survived more than 3 years without treatment4'. In another study, patients with synchronous solitary metastases of colorectal cancer had a 3-year survival rate of 17% compared to 1% for patients with multiple metastases6. It is possible that since the stage of the disease affects the outcome, early detection improves survival. Although isolated metastases exclusively confined to the liver are infrequent, a loco-regional treatment has the best chance of an effective palliation or even cure when applied to patients with metastatic spread confined to the liver. Liver resection is the only treatment which has the potential to cure a patient with liver tumours, however there seems to be an agreement to exclude patients with 4 or more metastases, extrahepatic disease, more than 50% hepatic replacement by tumour and lesions that cannot be resected with at least a margin of 10 mm7. Regrettably, the number of patients who fulfill these qualifications is limited and only a small number will readily benefit from liver resection7.
Chemotherapy of liver tumours has evolved from systemic to intra-arterial treatment with single drug to multiple drug combinations and to the innovative approach with delivery systems like the implantable pump for continuous administration of the treatment. The most consistently used chemotherapeutic drug has been 5-FU. Systemic administration of this agent for the treatment of liver metastases from colorectal cancer induces an objective response in between 15 The present study introduces chemonecrosis by alcohol as a new approach for localized dynamic destruction of hepatic metastases from colonic cancer. The results suggest that this approach offers a survival gain relative to other therapeutic modalities such as continuous intra-arterial chemotherapy, temporary dearterialization, and repeated intermittent dearterialization. In addition, chemonecrosis avoids the operative mortality of resectional surgery and also avoids its limitations be they tumour-related or operative risk-related. These advantages over resective treatment may be even more appreciated when the latter treatment is used only for palliation, because metastatic lesions in the liver cause pain, or when the patient may succumb from these lesions before being troubled by other sites of spread. Under these circumstances and even in the presence of other indicators of poor prognosis, the additive effect of palliation is a reasonable goal particularly if therapeutic success is to be interpreted in terms of the quality and comfort of the remaining part of a patient's life and not only the duration of this life. Although it has been reported 4 that in patients who had major hepatic resections the period of life without symptoms closely paralleled length of life so that patients were not made to live longer only to suffer more, chemonecrosis can avoid altogether the time and discomfort involved in major surgery in addition to being feasible in those patients considered a poor anaesthetic or surgical risk.
One of the most important points to note about chemonecrosis is that it requires no special devices or systems to be installed during surgery and can be applied whenever hepatic secondaries are noted. The advantage of this point can be readily realized when one recalls the proportion of colorectal cancer cases that do not appear to have metastasised to the liver, yet soon after their resection hepatic secondaries become obvious. Whether this last effect is produced by manipulations of the primary lesion, or represents metastases reaching the liver from affected lymphatics, or growth of metastases already present in the liver at the time of surgery to a size which allows detection, it can be effectively dealt with by percutaneous chemonecrosis. The dynamicity of this approach also means that any lesions which were missed can be treated the following session. In connection with this point the tremendous regenerative power of the liver enables these sessions to be repeated without any fear of serious consequences. In patients with colorectal cancer, exact diagnosis of the presence or absence of liver metastases is not always easy. Although it is not necessary to destroy all the hepatic secondaries during surgery for the primary lesion and may indeed be undesirable in poor risk patients or when it is thought unwise to increase operative time or extend the magnitude of surgery and increase its impact on the patient, the improved detectability of liver metastasis at the time of colorectal operation by the use of intraoperative ultrasonography overcomes the diagnostic limitations of percutaneous ultrasonography and CT scanning by detecting preoperatively unknown or nonpalpable lesions thereby helping operative decision making and providing a baseline for postoperative chemonecrosis. Considering the fact that this method is relatively simple, inexpensive and can be repeatedly applied without any apparent complications or mortality, it deserves a more detailed analysis through randomized trials to determine its exact place in the treatment of hepatic secondaries in comparison with current treatment options., The 
